Male/females of â?¥ 18 years of age at the time of consent <br/ >2 The patient who can and willing to provide written Informed Consent <br/ > Moderate Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection <br/ >confirmed by polymerase chain reaction (PCR) test /any other confirmatory tests <br/ >4. Patient with pneumonia with no signs of severe disease <br/ >5. If the patient presents any one of the following features: <br/ >- Respiratory rate â?¥ 24 breath/min to < 30 breath/min <br/ >- SpO2 (oxygen saturation) >90% to â?¤ 94% on room air <br/ >6. Patient/ patientâ??s LAR understands and is willing to participate in the clinical <br/ >study and can comply with clinical trial protocol requirements <br/ >The patient who has participated in another trial with an investigational drug within 1 <br/ >a month prior to this trial. <br/ >Patients who, in the judgment of the investigator will be unlikely to comply with <br/ >the requirements of this protocol

Male/females of â?¥ 18 years of age at the time of consent <br/ >2 The patient who can and willing to provide written Informed Consent <br/ > Moderate Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection <br/ >confirmed by polymerase chain reaction (PCR) test /any other confirmatory tests <br/ >4. Patient with pneumonia with no signs of severe disease <br/ >5. If the patient presents any one of the following features: <br/ >- Respiratory rate â?¥ 24 breath/min to < 30 breath/min <br/ >- SpO2 (oxygen saturation) >90% to â?¤ 94% on room air <br/ >6. Patient/ patientâ??s LAR understands and is willing to participate in the clinical <br/ >study and can comply with clinical trial protocol requirements <br/ >The patient who has participated in another trial with an investigational drug within 1 <br/ >a month prior to this trial. <br/ >Patients who, in the judgment of the investigator will be unlikely to comply with <br/ >the requirements of this protocol

N/A

N/A

Male/females of â?¥ 18 years of age at the time of consent <br/ >2 The patient who can and willing to provide written Informed Consent <br/ > Moderate Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection <br/ >confirmed by polymerase chain reaction (PCR) test /any other confirmatory tests <br/ >4. Patient with pneumonia with no signs of severe disease <br/ >5. If the patient presents any one of the following features: <br/ >- Respiratory rate â?¥ 24 breath/min to < 30 breath/min <br/ >- SpO2 (oxygen saturation) >90% to â?¤ 94% on room air <br/ >6. Patient/ patientâ??s LAR understands and is willing to participate in the clinical <br/ >study and can comply with clinical trial protocol requirements <br/ >The patient who has participated in another trial with an investigational drug within 1 <br/ >a month prior to this trial. <br/ >Patients who, in the judgment of the investigator will be unlikely to comply with <br/ >the requirements of this protocol

Male/females of â?¥ 18 years of age at the time of consent <br/ >2 The patient who can and willing to provide written Informed Consent <br/ > Moderate Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection <br/ >confirmed by polymerase chain reaction (PCR) test /any other confirmatory tests <br/ >4. Patient with pneumonia with no signs of severe disease <br/ >5. If the patient presents any one of the following features: <br/ >- Respiratory rate â?¥ 24 breath/min to < 30 breath/min <br/ >- SpO2 (oxygen saturation) >90% to â?¤ 94% on room air <br/ >6. Patient/ patientâ??s LAR understands and is willing to participate in the clinical <br/ >study and can comply with clinical trial protocol requirements <br/ >The patient who has participated in another trial with an investigational drug within 1 <br/ >a month prior to this trial. <br/ >Patients who, in the judgment of the investigator will be unlikely to comply with <br/ >the requirements of this protocol